In the News
Alzheimer’s Disease: An Epidemic in Rural America
GAP CSO, Dr. Richard Mohs, testified in front of US Senators about Alzheimer’s disease. He was quoted by RFD TV about how it affects rural America. While many of us are focused on the pandemic, chances are you know someone who is battling Alzheimer’s disease. Healthcare experts call it an epidemic in rural America. Lawmakers […]
Investment in Diversity and Rapid, Early Diagnostics Is Essential to the Search for a Cure for Alzheimer’s Disease
Global Alzheimer’s Platform Foundation® Chief Science Officer Dr. Richard Mohs testifies at Senate hearing about the Alzheimer’s crisis. Watch the full hearing at United States Senate Committee on Finance. Washington, DC (December 16, 2020) – Today, the Chief Science Officer of the Global Alzheimer’s Platform Foundation® (GAP), Dr. Richard Mohs, testified before the Senate Committee on Finance, […]
Running Clinical Trials in a Pandemic
GAP-Net site Stanford Neurology and Neurosurgery Clinical Trials at Stanford University talked about how researchers have gotten creative when it comes to continuing clinical trials during the COVID-19 Pandemic. At the beginning of the coronavirus pandemic, clinical trials came to a screeching halt. But as researchers and doctors have gained a better understanding of SARS-CoV-2, […]
Clinical Trial for Alzheimer’s Drug, Aducanumab Shows Promise
Citizen Scientist Mike O’Brien from GAP-Net site JEM Research is participating in the Biogen clinical trial for Aducanumab, which is under consideration by the US Food and Drug Administration (FDA). Sue and Mike O’Brien moved to South Florida about six years ago. One of her favorite sayings back then was ‘Really’? One night she realized […]
There is Reason for Hope as Alzheimer’s Awareness Month Comes to a Close
Dr. Chuang-Kuo Wu, the new Director of GAP-Net site Alzheimer’s Disease and Memory Disorders Center at Rhode Island Hospital spoke with NBC10 about the latest developments in #Alzheimers research. Watch the full interview or read the highlights below. As Alzheimer’s Awareness Month comes to a close, there is a reason for hope. There have been […]
Potential for an Alzheimer’s Treatment Appears to be Closer Than Ever
GAP-Net site Brigham and Women’s Hospital spoke to BioSpace about the emerging data in Alzheimer’s research and what that means for treatments. There may be nothing quite as gut-wrenching as sitting at the bedside of a loved one, watching helplessly as their life comes to an end. Perhaps the only thing more painful is when […]
STATEMENT: NEW DATA PLATFORM WILL EXPEDITE INNOVATION AND DRIVE COLLABORATION FOR ALZHEIMER’S DISEASE RESEARCH
Washington, DC (November 25, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding the Alzheimer’s Disease Data Initiative’s (ADDI) launch of the new Alzheimer’s disease data platform, AD Workbench. “Congratulations on the launch of AD Workbench, by our colleagues at the Alzheimer’s Disease Data Initiative (ADDI). The publicly […]
Advancing Alzheimer’s Research
2020 Citizen Scientist Cornerstone Award National Honoree Dr. Collins Lewis was featured for his efforts to encourage people from different racial backgrounds to participate in Alzheimer’s clinical trials. It’s not hard to understand why most medical research projects would benefit from a robust, varied set of study subjects. But sometimes, the pool of participants doesn’t […]
National Alzheimer’s Disease Awareness Month: Lou Ruvo Center
GAP-Net site Lou Ruvo Center in Las Vegas was featured for National Alzheimer’s Disease Awareness Month. The full interview can be found using the link at the bottom of this page. In Las Vegas, there are nearly 50,000 people battling the disease and more than 5 million around the country. The challenges of a loved […]
TRC-PAD Funnel Finally Touches Down
GAP was mentioned for our partnering with the European Prevention of Alzheimer’s Dementia (EPAD) to bring diversity and more volunteers to clinical trials. Recruiting asymptomatic participants for secondary prevention trials such as AHEAD 3-45 is no small feat. How do you find people who are well on the road to Alzheimer’s disease but feel fine, […]